Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
J Biotechnol ; 295: 41-48, 2019 Apr 10.
Article in English | MEDLINE | ID: mdl-30826446

ABSTRACT

The recent Ebola virus disease (EVD) outbreaks make the development of efficacious and low cost vaccines against Ebola virus (EBOV) an urgent goal. Multiepitopic vaccines allow a rational design rendering vaccines able to induce proper immune responses in terms of polarization and potency. In addition, the pathogen variants can be easily covered by including epitopes conserved among relevant isolates. Other important aspects to consider in vaccination are the costs associated to production, distribution, and administration of the vaccine. Plants provide an advantageous platform for this purpose, since they yield biomass at very low costs and some species can be used to formulate purification-free oral vaccines. In the present study, a multiepitopic protein called Zerola, which carries epitopes from the EBOV glycoprotein (GP), was designed based on immunoinformatic approaches and current experimental evidence on B cell protective GP epitopes. Moreover, expression studies performed in nuclear-transformed tobacco lines confirmed the capacity of the plant cell to synthetize the Zerola antigenic protein. The generation of this plant-based candidate vaccine is a step forward in the development of highly efficient and low cost EBOV vaccines.


Subject(s)
Ebola Vaccines , Ebolavirus/genetics , Protein Engineering/methods , Recombinant Proteins , Viral Envelope Proteins , Cells, Cultured , Ebola Vaccines/chemistry , Ebola Vaccines/genetics , Ebola Vaccines/metabolism , Epitopes/chemistry , Epitopes/genetics , Epitopes/metabolism , Hemorrhagic Fever, Ebola/prevention & control , Humans , Plant Cells , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Nicotiana/cytology , Nicotiana/genetics , Nicotiana/metabolism , Viral Envelope Proteins/chemistry , Viral Envelope Proteins/genetics , Viral Envelope Proteins/metabolism
2.
Hum Vaccin Immunother ; 11(9): 2322-8, 2015.
Article in English | MEDLINE | ID: mdl-26107442

ABSTRACT

Chagas disease is a major neglected tropical disease caused by persistent chronic infection with the protozoan parasite Trypanosoma cruzi. An estimated 8 million people are infected with T. cruzi, however only 2 drugs are approved for treatment and no vaccines are available. Thus there is an urgent need to develop vaccines and new drugs to prevent and treat Chagas disease. In this work, we identify T cell targets relevant for human infection with T. cruzi. The trans-sialidase (TS) gene family is a large family of homologous genes within the T. cruzi genome encoding over 1,400 members. There are 12 highly conserved TS gene family members which encode enzymatically active TS (functional TS; F-TS), while the remaining TS family genes are less conserved, enzymatically inactive and have been hypothesized to be involved in immune evasion (non-functional TS; NF-TS). We utilized immunoinformatic tools to identify HLA-A2-restricted CD8(+) T cell epitopes conserved within F-TS family members and NF-TS gene family members. We also utilized a whole-genome approach to identify T cell epitopes present within genes which have previously been shown to be expressed in life stages relevant for human infection (Non-TS genes). Thirty immunogenic HLA-A2-restricted CD8(+) T cell epitopes were identified using IFN-γ ELISPOT assays after vaccination of humanized HLA-A2 transgenic mice with mature dendritic cells pulsed with F-TS, NF-TS, and Non-TS peptide pools. The immunogenic HLA-A2-restricted T cell epitopes identified in this work may serve as potential components of an epitope-based T cell targeted vaccine for Chagas disease.


Subject(s)
Antigens, Protozoan/immunology , CD8-Positive T-Lymphocytes/immunology , Computational Biology/methods , Epitopes, T-Lymphocyte/immunology , Glycoproteins/immunology , HLA-A2 Antigen/metabolism , Neuraminidase/immunology , Trypanosoma cruzi/immunology , Animals , Antigens, Protozoan/genetics , Enzyme-Linked Immunospot Assay , Female , Glycoproteins/genetics , Humans , Interferon-gamma/metabolism , Mice, Transgenic , Neuraminidase/genetics , Protozoan Vaccines/administration & dosage , Protozoan Vaccines/immunology , Trypanosoma cruzi/genetics
5.
Hum Vaccin Immunother ; 8(7): 1006-9, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22777100

ABSTRACT

When the next pandemic emerges, will we be ready? Experts say that the number of animal to human "species jumps" is bound to increase as populations increase and the speed of travel between continents accelerates. Typical pandemic timelines no longer apply.(1) Pandemic H1N1 traveled the world in just weeks, as did SARS, despite major efforts to contain both outbreaks. The danger of emerging infectious disease to global health is compounded by the potential threat for malevolent bioengineering of existing pathogens and their deliberate dissemination.(2)


Subject(s)
Communicable Diseases, Emerging/epidemiology , Communicable Diseases, Emerging/veterinary , Pandemics , Vaccines/immunology , Zoonoses/epidemiology , Zoonoses/transmission , Animals , Communicable Diseases, Emerging/prevention & control , Communicable Diseases, Emerging/transmission , Global Health , Humans , Vaccines/administration & dosage , Virus Diseases/epidemiology , Virus Diseases/prevention & control , Virus Diseases/transmission , Virus Diseases/veterinary
SELECTION OF CITATIONS
SEARCH DETAIL
...